RxDoctor Payments Data

Kate West

Family · Weed, CANPI 1295190890

Payments from drug & device makers

$521in general payments, 2019–2025

Across 37 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$167
  • Novo Nordisk$148
  • AstraZeneca$67
  • Biohaven Pharmaceutical Holding Company Ltd.$46
  • Pfizer$40
  • Boehringer Ingelheim$25
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$521 in reported general payments places this provider in the 60th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$3,198
Medicare patients
94
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$41,968
EliquisApixaban28$35,651
OzempicSemaglutide19$26,059
Spiriva RespimatTiotropium Bromide14$10,072
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,580
FarxigaDapagliflozin Propanediol11$8,375
BelsomraSuvorexant12$5,309
OxycontinOxycodone Hcl12$4,646
Arnuity ElliptaFluticasone Furoate16$4,311
Breo ElliptaFluticasone/Vilanterol11$3,698
Albuterol Sulfate HfaAlbuterol Sulfate78$3,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,421
Estradiol32$1,967
Rosuvastatin Calcium128$1,954
Diclofenac Sodium28$1,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$41,96828 claims
PfizerEliquis$40$35,65128 claims
Novo NordiskOzempic$148$26,05919 claims
Boehringer IngelheimSpiriva Respimat$25$10,07214 claims
AstraZenecaFarxiga$67$8,37511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,634 family providers in California.

Other family in Weed

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →